JAMES TREACE - 28 Apr 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for James T. Treace
Issuer symbol
TMCI
Transactions as of
28 Apr 2023
Net transactions value
-$1,252,695
Form type
4
Filing time
02 May 2023, 21:00:10 UTC
Previous filing
31 Mar 2023
Next filing
13 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale $1,000,264 -40,000 -4.4% $25.01 871,441 28 Apr 2023 Direct F1, F2
transaction TMCI Common Stock Sale $191,283 -7,640 -0.88% $25.04 863,801 01 May 2023 Direct F1, F3
transaction TMCI Common Stock Sale $61,148 -2,360 -0.27% $25.91 861,441 01 May 2023 Direct F1, F4
holding TMCI Common Stock 556,183 28 Apr 2023 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.4100 to $25.3050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5400 to $25.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5400 to $26.1500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.